logo
Fale dam lo ruang i siizung panh a hauh tikah theihfian a biapi mi hna

Fale dam lo ruang i siizung panh a hauh tikah theihfian a biapi mi hna

SBS Australia20 hours ago

If your child needs urgent help call Triple Zero for an ambulance.
Triage is the initial point of care in a hospital's emergency department.
Parents should know what doctors think is wrong with their children and the diagnosis when discharged from the emergency department. A Sydney-based parent, Bethany Girling, knew she had to rush her daughter to the children's emergency department when she spotted alarming signs and symptoms on her. "She had really high fevers. They were going on for probably about four days at this stage. We've been to the doctor, and she was on antibiotics, but she just wasn't getting better," Ms Girling says.
Ms Girling noted that her daughter wasn't drinking, her chest was working hard, and her ribs were sucking in. Without hesitation, she rushed her to the nearest children's emergency department.
Paediatric Emergency Doctor Matthew O'Meara When to go the emergency department "That instinct can come from a number of things. Sometimes they might notice their child being less alert, less active, less playful. It may be that they've got breathing problems. It maybe they look a poor colour, they look much paler than usual or mottled or bluish," Dr O'Meara says. He adds that they may not be drinking much or passing much urine, or sometimes, their parents have that gut feeling or instinct that something isn't right. If you are worried about your child, Dr O'Meara points to the health care services available that can help, starting with calling Triple Zero for an ambulance. "There're a few doors into the health system. The most urgent door is by calling triple zero for an ambulance. And l would do if you are really concerned that your child needs help straight away, that they're finding it very difficult to breathe, that they have a very poor colour, that you think they've stopped breathing or they're not conscious or they are having a fit," he explains. An emergency department is a suitable place if they require assistance more urgently. Dr O'Meara says if your child is experiencing some difficulty breathing—though it's not severe—has a slightly unusual colour, is drinking less than usual, and appears less active than normal, it's essential to seek help soon at the emergency department.
If you feel that something isn't quite right and you need to see them later today or tomorrow, visiting a general practice or an urgent care centre would be a good option.
If you are worried about your child and need help immediately call Triple Zero for an ambulance. Credit: kali9/Getty Images What to expect in the emergency department So, what happens next if you find yourself in the emergency department? Triage is the initial point of care in a hospital's emergency department. It is a system designed to prioritise patients based on the severity of their condition. She explains that the triage person is a nurse. They can quickly look over your child and assess their condition based on the urgency of their need to be seen. "They're given a triage category based on that urgency. So, the most critically unwell patients will be seen first. And then the less urgent patients will then be seen in a timely manner," Ms Bold says.
Ms Bold explains that triage prioritises cases based on urgency for life-threatening conditions, ensuring that the most critical cases receive the highest priority.
Do I have to pay? In Australia, visits to public hospital emergency departments are free for Medicare cardholders. However, if you attend a private hospital emergency department, you will need to pay a fee.
Ambulance services also typically incur charges in most states, with fees varying depending on where you are. Some people, such as concession cardholders or those with private health insurance, may be exempt from these costs.
Your child's health details can include allergies, medications, and pre-existing conditions. Credit: ozgurcankaya/Getty Images Tips for parents and follow up care If you can prepare before heading to the emergency department, Ms Bold suggests having your primary details handy. "When you come into our emergency department, we really like it when parents have their Medicare card available or any health details available and their address and phone number so we can contact them if we need to," Ms Bold says. Your child's health details can include allergies, medications, and pre-existing conditions. It may also include symptoms when they started, what made them worse, and any treatment you've tried. Dr Matthew O'Meara explains what happens next if your child's case is processed to be seen next in the queue. "They will be seen by other nurses, doctors and nurse practitioners . Who will assess them in more detail, go through the story in more detail, examine them and work out if any investigations are necessary, like blood tests or x-rays can assess their response to treatment," he explains. He adds that children may need to be observed for a while before a decision is made about their care. Most children can go home from the emergency department. Still, some may need to be admitted to the hospital for an extended period of care. If your child's case is less urgent than others in the emergency department, you might face a longer wait time.
At the end of your visit to the children's emergency department, you should have learned several important things about your child's health situation.
If your child's case is less urgent than others in the emergency department, you might face a longer wait time. Source: iStockphoto / chameleonseye/Getty Images Dr O'Meara explains that parents should know what doctors think is wrong with their children and the diagnosis. They should tell you what you should expect to happen at home and what things should make you concerned and need to seek medical help. Doctors will also advise you on managing simple things like pain, fever, and fluids. Dr O'Meara says that health practitioners at the emergency department should talk to you about medications and treatments, their effects, and any possible side effects. They will also advise you on where to go if your child needs care after going home from the emergency. "Ideally, we don't just talk to you about these things. We give you written information in factsheets, and ideally in your preferred language as well, to describe what's going on, and we should communicate with your normal treating doctor about what's going on. So, send them a discharge summary or give you a discharge summary to take to your doctor," Dr O'Meara adds. If your family prefers a language other than English, you can access a free translating and interpreting service to help communicate with health services by calling 13 14 50. Now you know what to expect if you have to go to the emergency department, but you can also learn about the English words and phrases you may come across in these situations. Listen to SBS Learn English episode 85 to improve your English and feel more confident when talking to hospital staff. For more information, visit your local hospital's website or Health Direct at healthdirect.gov.au .
Thanks to the Sydney Children's Hospitals Network for suggesting this topic. Factsheets (in several languages) and further information is available on the SCHN website . Subscribe or follow the Australia Explained podcast for more valuable information and tips about settling into your new life in Australia.
Do you have any questions or topic ideas? Send us an email to australiaexplained@sbs.com.au

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Wayne and Noah Smith gun deaths inquest calls for licensing reform
Wayne and Noah Smith gun deaths inquest calls for licensing reform

ABC News

time29 minutes ago

  • ABC News

Wayne and Noah Smith gun deaths inquest calls for licensing reform

A coronial inquest has heard of the need for reforms to NSW gun licensing after a mentally unwell man was handed back his guns less than six months before he used one to kill his son and then himself. Warning: This story contains details that readers may find distressing. Wayne Smith killed his 15-year-old son Noah as he lay sleeping in their Yamba home in the early hours of June 1, 2023, before turning the weapon on himself. State Coroner Teresa O'Sullivan has heard testimony from doctors, police and the NSW Firearms Registry about the circumstances that led to the 58-year-old being reissued with his gun licence despite having a history of mental illness. In her closing statement to the inquest, Counsel Assisting, Donna Ward SC, made several recommendations to improve gun licensing processes, including making it mandatory for GPs to report concerns about patients who own a gun. Ms Ward said there had been a breakdown in communication between the health professionals who had been treating Mr Smith. "We don't have any simple solutions to that problem," she said. The inquest also heard about a lack of community and hospital options in northern News South Wales for mental health treatment. Ms Ward said that at the time of Wayne and Noah Smith's deaths there were deficiencies in NSW Firearms Registry processes. Since then, the Firearms Legislation Amendment Bill 2022 has enacted new laws relating to gun ownership and licensing. Ms Ward made a series of proposed recommendations for the Minister for Police and the Police Commissioner to consider in the post implementation review of those reforms. These included a standard question during GP consultations about whether a patient held a gun licence, and a statutory obligation for GPs to report to police if they had safety concerns for a patient who held a gun licence. She also proposed two separate mental health risk assessments for anyone who had experienced suicidal ideation in the previous five years. Ms Ward proposed gun licence holders be required to give a good reason for acquiring any additional firearms, and the Firearms Registry be more rigorous in assessing hunting and vermin control as the genuine reason for the issue of a gun licence. Family of Wayne and Noah Smith made submissions to the inquest in closed court this afternoon. The Coroner will hand down formal recommendations arising from the inquest in coming months.

'It's like fauxtox!' The $66 face cream that women over 40 swear by
'It's like fauxtox!' The $66 face cream that women over 40 swear by

Daily Telegraph

time3 hours ago

  • Daily Telegraph

'It's like fauxtox!' The $66 face cream that women over 40 swear by

Don't miss out on the headlines from Lifestyle. Followed categories will be added to My News. I can't really explain it, but you know that fresh smell you get when you leave a really good facial? Or the lingering scent of essential oils on your skin after a relaxing massage? That's what it smells like. "It" being a new face cream I've been using and loving. And as it turns out, I'm not the only one. Let's rewind a little. Women over 40 - or even earlier for the really unlucky ones - have been speaking openly about perimenopausal symptoms affecting their everyday life more so than ever before. They're coming together in support, and even educating the clueless men in their lives about why we are sometimes so ragey about the way they're stacking the dishwasher. Want to join the family? Sign up to our Kidspot newsletter for more stories like this. Perimenopause symptoms suck Yes, there's the mood and menstrual cycle changes, as well as hot flushes, irritability, mood swings, night sweats, sleep disruption, and changes in your libido. But what about your skin? When discussing peri symptoms, no one seems to talk about how lifeless, blotchy, and puffy your skin can get. According to my GP, I'm "not there yet" but that's certainly news to my face! Ever since I hit 40, I've been blessed with the occasional outburst of adult acne, far too much pigmentation, and just general dullness. So when I heard that one of my favourite local brands had released a cream just for women approaching their menopause phase in life, you bet I wanted to give it a try. And before you ask... NO, this isn't sponsored! I genuinely want to share it with you. RELATED: The $52 moisturiser that banishes adult acne Antipodes' Jasmine Flower face cream retails at $66. Image: Supplied The $66 face cream for women approaching menopause New Zealand skincare brand, Antipodes, recently launched their Jasmine Flower Menopause Facial Cream (RRP $66, 60ml) - a day cream that targets women who are suffering from visible symptoms of perimenopause and full-blown menopause. It's silky, cooling, smells divine with the scent of jasmine (see notes above about the smell you get leaving a facial), and targets redness, fine lines and wrinkles. When I applied the cream for the first time, I was a little worried about the thickness - it had the same consistency as a 50+ sunscreen. But within seconds of rubbing it in, the white cream soaks into your skin, leaving it super moisturised and your face full of life. "Formulated for sensitive skin, it helps with visible signs of menopause such as redness, severe dehydration, hormonal blemishes, and signs of ageing, to smooth and balance your evolving complexion," the website description reads. Born and bread in New Zealand... just for your peri skin needs. Image: Supplied "Organic oat extract calms red, irritated, and sensitive skin. Peptides from chamomile and fermented jasmine flowers help relax lines and wrinkles. New Zealand avocado oil, with collagen boosting properties, fused with manuka honey to ease signs of ageing whilst reducing blemishes." I caught a glimpse of myself in the mirror a few hours after applying, and my face not only felt great, it made me look alive again! The redness and puffiness I woke up with were gone, and I was left with a radiant base that really needed nothing on top. It was like fauxtox in a jar! RELATED: What you need to know about perimenopause The women have spoken! Before launching the day cream, the Antipodes team conducted an independent clinical study with 50 women suffering from sensitive skin. After trialling it, 78% said the cream visibly calmed their irritated skin. Jennie is just one of those women who has seen a visible improvement after consistently using the cream for three weeks. "I have loved this product, it's not heavy but covers well and really left my skin feeling hydrated. I have three types of rosacea: in my eyes, the red skin one and papulopustular, and this cream has looked after all three," she praised. Jennie suffered from a heap of skin issues, which the cream seemed to settle. Image: Supplied Hanni also gave it a 5-star review, claiming she saw a "huge improvement" in her skin's moisture level. "My skin blotches are disappearing after only two weeks," she confessed. And the glowing (boom boom) reviews keep coming. "The plumpness and reduced tightness are game changers... My combination skin feels perfectly balanced—no excess oil, just smooth and hydrated," a fan wrote online. Another agreed: "This product is amazing - leaves your skin feeling and looking great. I'm sure my skin looked more youthful after using it. Love the scent too." "Lovely and smooth, my skin loves it," another fan added. Try it out for yourself! Grab a jar from Priceline, David Jones, Chemist Warehouse, Adore Beauty, Healthylife, Nourished Life as well as independent pharmacies and health shops across Australia. Just don't expect it to calm your nerves around your annoying spouse.. that will still continue! Originally published as 'It's like fauxtox!' The $66 face cream that women over 40 swear by

Health Check: A pancreatic cancer ‘cure' has been elusive, but Amplia may have cracked the nut
Health Check: A pancreatic cancer ‘cure' has been elusive, but Amplia may have cracked the nut

News.com.au

time5 hours ago

  • News.com.au

Health Check: A pancreatic cancer ‘cure' has been elusive, but Amplia may have cracked the nut

Amplia shares soar almost 50% on news of a 'complete response' in a patient with metastasised pancreatic cancer Syntara and Kazia also report progress with their cancer drug candidates Emvision pockets $5 million of non-dilutive grant funding Has Amplia (ASX:ATX) cured pancreatic cancer, one of the deadliest tumour types? The drug developer reports a 'pathological complete response' in an advanced (metastatic) pancreatic cancer patient – an 'extremely rare' event. A pathological complete response means there are no signs of cancer in tissue examined by a pathologist following surgical removal. The treatment appeared to have reduced the tumour to a size where both the primary tumour in the pancreas and secondary liver tumours could be excised. Amplia's drug candidate AMP-945 (narmafotinib) is a focus kinase (FAK) inhibitor. FAKs are not cuss words but a type of protein overexpressed in pancreatic cancers. Dubbed Accent, Amplia's trial uses narmafotinib in combination with standard chemotherapy gemcitabine. The company is carrying out the phase 1b/2a trial at seven local sites and five in South Korea. The first stanza (1b) already has assessed dosing safety and tolerability The company notes about 5% of patients with non-metastatic pancreatic cancer achieve a pathological compete response. The bar for cancers that have spread is much higher. 'This is wonderful news for the patient and the clinical team involved,' Amplia CEO Dr Chris Burns says. 'We firmly believe this outcome further demonstrates the promising activity narmafotinib, on top of standard-of-care, is showing in treating advanced pancreatic cancer.' While one swallow doesn't make a summer, investors pushed Amplia shares as much as 47% higher before profit takers moved in. Syntara's blood cancer program looks the goods Amplia chief Chris Burns co-developed the myelofibrosis (blood cancer) drug Ojjaara, one of the few home-grown remedies to be approved by the US Food and Drud Administration (FDA). Can Syntara (ASX:SNT) follow suit? The company reports further data from its phase II trial, evaluating its drug candidate SNT-5505 in combo with the standard-of-care drug ruxolitinib. The patients had been treated with ruxolitinib for at least three years, so had enhanced symptoms such as enlarged spleen size and blood counts 'indicative of high disease burden.' The results showed eight of eleven evaluable patients (73%) achieved a reduction of more than 50% at 24 weeks. This was measured by a standard gauge called TSS50. The patients achieved a median improvement of 39%. Four out of nine patients (44%) had a spleen volume reduction of 25% at week 24 or beyond. The ongoing trial enrolled 16 patients with intermediate or high-risk myelofibrosis, for 52 weeks of treatment. However, five dropped out by the 24-week mark, a 'withdrawal rate consistent with that seen in other myelofibrsis studies of patients with similar disease severity." Eight patients reaching 38 weeks showed an average 56% reduction in symptoms. Of these, Five patients reaching 52 weeks showed a 63% decline. The company plans to release the final study results after the September quarter, when the remaining three patients have completed their treatment. Syntara intends to meet with the FDA in the September quarter to discuss the design of a pivotal phase 2c/3 study. The company announced the results on Friday and aired them at the weekend's European Hematology Association conference in Milan. Kazia's cancer news from the Nasdaq Further afield, the Nasdaq listed and formerly ASX-domiciled Kazia last week said its immunotherapy candidate paxalisib showed 'anti-tumour activity in advanced breast cancer'. In collaboration with the Queensland Institute of Medical Research (QIMR) Berghofer, Kazia is carrying out a 24-patient, phase Ib trial in combo with the standard-of-care pembrolizumab (Keytruda). The Sydney-based Kazia licensed the tech from the QIMR. The company said the data provided 'strong scientific and translational rationale for continued development of paxalisib as part of immunotherapy-based regimens.' The dual-listed Kazia delisted from the ASX last November, to reduce costs. The experience of ASX biotechs joining the Nasdaq has been patchy, to put it mildly. But Kazia shares last week more than doubled on the news. The pain of Mayne stays mainly on display Mayne Pharma (ASX:MYX) will forge ahead with a planned shareholder meeting to approve its takeover scheme of arrangement, despite receiving a second 'dear John' letter from suitor Cosette. Mayne says the correspondence – almost certainly not written on rose-scented parchment – affirms that Cosette intends to terminate the scheme implementation deed (SID) on the grounds of alleged breaches. It maintains Cosette has 'no lawful basis' to terminate the SID. So, as it stands Mayne shareholders will file into Melbourne's Intercontinental Hotel on Wednesday to vote on an offer that a reluctant suitor has no intention of executing. With no whiff of rapprochement, this one is headed for the courts. Emvision wins $5 million government grant There's no better funding than the non-dilutive variety, as EMvision Medical Devices (ASX:EMV) attests. The feds have awarded Emvision a $5 million federal government grant, to further the development of its First Responder portable brain scanner. The funds are by way of an Australian Government Industry Growth Program (IGP) Commercialisation and Growth Grant. First Responder distinguishes between bleed and clot strokes at the scene and is designed to be used by ambulances and by paramedics. The device should shorten diagnosis time – a crucial element in the patient getting the right treatment. 'First Responder … is a genuine world first product with potential to transform the landscape of pre-hospital stroke and traumatic brain injury care,' Emvision chief Scott Kirkland says. '… quite simply, if we can help save time, we can help save lives and reduce disability.' As of the end of March, Emvision had $12.5 million of cash and expected $800,000 of funding from the Australian Stroke Alliance this financial year. Heramed in maternity monitoring collab Still on non-dilutive funding, foetal monitoring device developer HeraMED (ASX:HMD) has partnered with RMIT University (RMIT) and the Digital Health Cooperative Research Centre in a research partnership. The $1.245 million project will delve into better ways to deliver maternity care for culturally and linguistically diverse women. As is the way in the modern world, the project involves refining AI-based predictive health models and tools. This is based on monitoring and collecting data on 200 pregnant women. 'The initiative will use a combination of clinical, biometric, lifestyle and genetic data, with a focus on diversity, inclusion, and clinical applicability," Heramed says. Heramed is contributing $250,000 over the 18-month project and the other parties are contributing the rest via grant funding. 'With 51% of Australians having at least one parent born overseas, the need for culturally informed healthcare is critical and relevant,' says Heramed CEO Anoushka Gungadin.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store